Company profile: Vivet Therapeutics
1.1 - Company Overview
Company description
- Provider of AAV-based gene therapies for orphan diseases, including VTX-801 for Wilson’s disease, VTX-802 for Progressive Familial Intrahepatic Cholestasis Type 2, VTX-803 for Progressive Familial Intrahepatic Cholestasis Type 3, VTX-804 for Citrullinemia Type 1, and VTX-806 for Cerebrotendinous Xanthomatosis, plus VTX-PSM, a non-integrative viral technology for sustainable transgene expression, partnered with FIMA/CIMA.
Products and services
- VTX-PSM: Non-integrative viral-based technology enabling sustainable transgene expression in growing organs and tissues without genome integration, allowing persistence during organ growth
- VTX-801: AAV-based gene therapy for Wilson’s disease delivering a corrective ATP7B gene to the liver to address copper regulation
- VTX-802: Gene therapy targeting Progressive Familial Intrahepatic Cholestasis Type 2, delivering a codon-optimized version of the BSEP gene.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vivet Therapeutics
Veritas Genetics
HQ: United States
Website
- Description: Provider of a genetic testing platform that detects a wider range of gene variations than typical next-generation sequencing and offers screening for hereditary breast and ovarian cancer risk, empowering people to live healthier and longer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veritas Genetics company profile →
Inflammatix
HQ: United States
Website
- Description: Provider of rapid immune system diagnostics and sepsis-focused research. Offers the TriVerity Acute Infection and Sepsis Test System—Myrna Instrument and TriVerity Test—to identify bacterial or viral infections and assess risk of severe illness; conducts therapy response prediction to refine sepsis subtypes and therapy selection; collaborates on drug and device development; and participates in the SUBSPACE Consortium.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inflammatix company profile →
KEW
HQ: United States
Website
- Description: Provider of personalized oncology management through DNA-based genomic testing and interpretation, including CANCERPLEX profiling of 400+ cancer genes to match targeted therapies; GENEKEEPER variant interpretation software; end-to-end tumor sequencing and personalized reporting; molecular lab enablement for CANCERPLEX; physician sample-to-report services; and patient and caregiver support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KEW company profile →
Personal Genome Diagnostics
HQ: United States
Website
- Description: Provider of patient-specific cancer genome analysis tools and comprehensive genomic profiling kits, including PGDx elio tissue complete (FDA cleared, CE-IVD marked) for in-house tumor profiling of over 500 genes identifying somatic mutations (SNVs, indels, TMB, MSI, select amplifications/translocations); PGDx elio plasma complete liquid biopsy for research across over 500 genes (SNVs, indels, bTMB, MSI, LOH); and PGDx elio plasma focus targeting 33 cancer genes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Personal Genome Diagnostics company profile →
SensID
HQ: Germany
Website
- Description: Provider of reference materials for DNA diagnostic procedures, designed for R&D, validation, external control, accreditation preparation, round robin tests, and integration into diagnostic devices or kits. Offerings include cfDNA multiplex sets for liquid biopsy (AKT1, BRAF, ERBB2, KRAS, PIK3CA; EGFR for NSCLC) and FFPE reference standards (PIK3CA variants, MSI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SensID company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vivet Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vivet Therapeutics
2.2 - Growth funds investing in similar companies to Vivet Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vivet Therapeutics
4.2 - Public trading comparable groups for Vivet Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →